Drug intelligence / Profile preview

lidocaine + prednisolone

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intraarticular, Intrabursal, Intralesional, Soft Tissue Injection, Intrasynovial

Overview

Lidocaine + prednisolone is a medicinal compound that combines lidocaine, a local anesthetic, with prednisolone, a corticosteroid. This combination provides both immediate pain relief through lidocaine's action of blocking sodium channels in neurons, and longer-term anti-inflammatory effects through prednisolone's immunosuppressive and anti-inflammatory properties. It is primarily used for local administration to treat various inflammatory conditions.

Brand names: DEPO-MEDROL with Lidocaine
Other names: Lidocaine and Prednisolone Mixture

Targets

GR (Glucocorticoid receptor)NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on lidocaine + prednisolone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lidocaine + prednisolone.

Explore the full profile